← Eichor
Study identifier: NCT06561178 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)

Condition: Esophageal Squamous Cell Carcinoma  ·  Sponsor: Sun Yat-Sen University Cancer Center

PhaseN/A
Planned participants50
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study or is to explore the correlation between dynamic changes in postoperative circulating tumor DNA (ctDNA) and recurrence risk using a novel, tumor-informed ctDNA detection technique, thus laying the foundation for further promoting ctDNA detection to guide postoperative adjuvant therapy decisions. This study focuses on patients with esophageal squamous cell carcinoma who did not achieve pCR following neoadjuvant therapy combined with surgical resection. The main question it aims to answer is: Is there a correlation between postoperative ctDNA changes and tumor recurrence? Participants will be asked to undergo postoperative ctDNA detection.

This description comes directly from the study's public registry record.

Talk to the study team

Hong Yang, MD  ·  86-020-87343932  ·  yanghong@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06561178